This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

Medtronic Receives Health Canada License For Deep Brain Stimulation Therapy In Refractory Epilepsy Patients

Stocks in this article: MDT

Medtronic, Inc. (NYSE: MDT) today announced that it has received from Health Canada a license for Medtronic Deep Brain Stimulation (DBS) Therapy for refractory epilepsy patients. Medtronic DBS therapy for refractory epilepsy delivers controlled electrical pulses to a location inside the brain which is involved in seizures.

The Health Canada license was based on data collected in Medtronic’s clinical trial called SANTE ® (Stimulation of the Anterior Nucleus of the Thalamus in Epilepsy). The SANTE trial was a prospective, randomized, double-blind pivotal study to evaluate the use of DBS therapy for patients with medically refractory epilepsy with partial-onset seizures. The trial collected data from 110 patients who were implanted with a Medtronic DBS system at 17 centers in the United States.

Medtronic DBS Therapy for refractory epilepsy is also approved in Europe. The therapy is not currently approved by the U.S. Food and Drug Administration for use in the United States for the treatment of refractory epilepsy.

To date, more than 85,000 patients worldwide have received Medtronic DBS therapy. The therapy is currently licensed in Canada and approved in other regions including the European Union and the United States, for the treatment of the disabling symptoms of essential tremor, advanced Parkinson's disease and dystonia, for which approval in the United States is under a Humanitarian Device Exemption (HDE) 1. The therapy is also approved for the treatment of severe, treatment-resistant obsessive-compulsive disorder not adequately controlled by medications in the European Union and in the United States under an HDE 2.

“Medtronic is a pioneer in the field of neuromodulation,” said Lothar Krinke, Ph.D., vice president and general manager for the Deep Brain Stimulation business in Medtronic’s Neuromodulation division. “We are proud of the expansion of indications to include epilepsy, which will allow more patients to benefit from our DBS therapy. This Medtronic First innovation provides a viable option for patients who are not responsive to other therapies. This follows closely the Canadian launch of the RestoreSensor neurostimulator for chronic pain, another Medtronic first. ”

Medtronic’s Leadership in NeuromodulationMedtronic developed and leads the field of neuromodulation, the targeted and regulated delivery of electrical pulses and pharmaceuticals to specific sites in the nervous system. The company’s Neuromodulation business includes neurostimulation and implantable, targeted drug delivery systems for the management of chronic pain, common movement disorders, spasticity and urologic and gastrointestinal disorders.

Medtronic of Canada’s innovative neuromodulation portfolio includes the following technologies:

  • RestoreSensor neurostimulator with AdaptiveStim™ technology: the world’s first and only pain-management device designed to sense a change in the patient’s body position or activity and automatically adjust stimulation to deliver the right amount of pain relief.
  • Activa® PC (Primary Cell), Activa® SC (Single Channel), and Activa® RC (Rechargeable Cell): The Activa line of neurostimulators includes the first rechargeable neurostimulator in Canada, with all three products featuring the most advanced multi-programming capabilities in Canada. Activa® PC is the neurostimulator licensed for use in refractory epilepsy. Only the ACTIVA family of neurostimulators provides clinicians with the ability to deliver stimulation in constant voltage or constant current mode, providing physicians with a choice based on their preference and clinical needs.

About Medtronic of Canada Ltd.Medtronic of Canada ( www.medtronic.ca) sells, services and distributes Medtronic products in Canada: medical devices used in cardiovascular medicine, diabetes, spinal and neurosurgery, and ear, nose and throat surgery. Medtronic of Canada employs over 745 Canadians, it is headquartered in Brampton, Ontario, has regional offices in Vancouver and Montreal and an atrial fibrillation (AF) ablation catheter manufacturing facility – Medtronic CryoCath – in the Montreal metropolitan area.

About MedtronicMedtronic, Inc. ( www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission.

1 Humanitarian Device in the U.S.: The effectiveness of this device for the treatment of dystonia has not been demonstrated. 2 Humanitarian Device in the U.S.: The effectiveness of this device for the treatment of obsessive-compulsive disorder has not been demonstrated.



1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,814.94 -2.96 -0.02%
S&P 500 2,067.03 -2.38 -0.12%
NASDAQ 4,758.2520 +3.36 0.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs